<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641953</url>
  </required_header>
  <id_info>
    <org_study_id>01-004A</org_study_id>
    <nct_id>NCT00641953</nct_id>
  </id_info>
  <brief_title>IMX-150 Cream for Diabetic Neuropathy</brief_title>
  <official_title>A Randomized, Phase II, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study of an Aqueous Topical Formulation of Nitroglycerin, IMX-150, in the Treatment of Pain in Diabetic Peripheral Neuropathy of the Feet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Procris Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Procris Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of two different dose of IMX-150 to
      that of placebo (non-active) in the treatment of diabetic peripheral neuropathy pain of the
      feet.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline to endpoint (Day 29) in the average of neuropathic foot daily pain &quot;24 - Hour Average Pain&quot; scores</measure>
    <time_frame>Weekly average of &quot;24-hour Average Pain&quot;</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in weekly average sleep disturbance</measure>
    <time_frame>daily</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMX-150 (0.3%) 0.5 g topically BID each foot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMX-150(0.6%) 0.5 g topically BID to each foot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.5 g topically BID to each foot for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMX-150</intervention_name>
    <description>(0.3%) 0.5g topically BID to each foot for 4 weeks</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMX-150</intervention_name>
    <description>(0.6%) 0.5g topically BID to each foot for 4 weeks</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 g topically BID to each foot for 4 weeks</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have sufficient command and understanding of the English language to complete
             diaries and questionnaires

          -  If female, may not be pregnant or lactating

          -  Can be treated on an outpatient basis

          -  Has a clinical diagnosis of Type-1 or Type II diabetes with: confirmed diagnosis of
             diabetic distal symmetrical sensorimotor polyneuropathy and bilateral pain in the feet
             for at least 3 months.

          -  Must have a hemoglobin A1C value of 11% or less that is stable under treatment

          -  Agrees to use the test creams as specified for the 4 week period

          -  Willing to not use any other medications, including investigational medications, to
             treat pain symptoms of Diabetic Neuropathy while in study.

        Exclusion Criteria:

          -  Currently using any nitrate medications

          -  Currently using Viagra®, Levitra®, Cialis® or other phosphodiesterase 5 inhibitors
             medications for erectile dysfunction

          -  Currently treated for symptoms of diabetic neuropathy, including but not limited to
             Lyrica®, Cymbalta® and transcutaneous stimulation

          -  Not on a stable dose for at least 4 weeks prior to study screening of other
             vasodilators required for underlying conditions

          -  Know allergy to Nitroglycerin, propylene glycol or common moisturizing creams

          -  History of migraine, cluster or vascular headaches, chronic pain with greater pain
             intensity than the pain of diabetic neuropathy or other chronic pain condition within
             the region of the diabetic peripheral neuropathy

          -  Amputation of more than one toe per foot

          -  Neurological disorder or skin condition that may alter local sensation in the feet

          -  History of unstable medical problem, clinically significant screening laboratory test
             or any current medical condition that would contraindicate the administration of the
             study mediation, interfere with the study evaluations, or interfere with the patient's
             ability to comply with the study

          -  History of drug (including cannabinoid) or alcohol abuse within the past year

          -  Cognitive or language difficulties that would impair completion of the pain assessment
             tool

          -  Within the past 3 months, have had either a myocardial infarction, uncontrolled
             hypotension, or uncontrolled hypertension

          -  Participated in a study of any investigational drug within 4 weeks or 5 half-lives of
             the drug, whichever is longer, prior to Screening

          -  Major abdominal, thoracic or vascular surgery within 6 months of the first dose of
             study medication

          -  Open lesions in the area where the cream is to be applied

          -  Fertile patients who are unable or unwilling to comply with the contraceptive
             requirements during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Yeramian, MD</last_name>
    <role>Study Director</role>
    <affiliation>VP Medical Affairs</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Meriden Research</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Awareness</name>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <zip>33458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Research Associates, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula Research</name>
      <address>
        <city>Ormond Beach</city>
        <state>Florida</state>
        <zip>32174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Medical Research</name>
      <address>
        <city>Oviedo</city>
        <state>Florida</state>
        <zip>32765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meridien Research</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hampton Roads Center for Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>June 13, 2008</last_update_submitted>
  <last_update_submitted_qc>June 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matthew A. Gonda, PhD</name_title>
    <organization>Procris Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Foot Pain</keyword>
  <keyword>Diabetic Neuropathy Pain</keyword>
  <keyword>Diabetic Peripheral Neuropathy foot pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

